Aurinia Pharmaceuticals (AUPH) Stock Analysis

What Aurinia Pharmaceuticals does

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

Key metrics

ETFs linked to AUPH

Broad-market and Healthcare sector ETFs an investor holding Aurinia Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how AUPH fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals trades under the ticker AUPH on NASDAQ.

Which exchange is AUPH listed on?

AUPH is listed on NASDAQ.

What sector does Aurinia Pharmaceuticals operate in?

Aurinia Pharmaceuticals is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze AUPH in a portfolio?

PortView shows AUPH's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.